Abstract：
OBJECTIVE: To estimate vaccine effectiveness (VE) and duration of protection of single primary and booster immunisation with meningococcal C (MenC) and ACWY (MenACWY) conjugate vaccines in preventing MenC invasive meningococcal disease (IMD).
METHODS: We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).
RESULTS: We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 - 96.1) and 84.1% (41.5 - 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.
CONCLUSIONS: A single dose of MenC or MenACWY vaccine at 12-23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.
METHODS: We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12-23 months for primary and 6-18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).
RESULTS: We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 - 96.1) and 84.1% (41.5 - 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.
CONCLUSIONS: A single dose of MenC or MenACWY vaccine at 12-23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.
摘要：
目的：评估用脑膜炎球菌C（MenC）和ACWY（MenACWY）结合疫苗单次初次和加强免疫在预防MenC侵袭性脑膜炎球菌疾病（IMD）中的疫苗有效性（VE）和保护持续时间。
方法：我们对年龄为12-23个月的初次和6-18岁的加强免疫参与者的VE和免疫原性（rSBA/hSBA滴度）的研究进行了系统评价（最后一次搜索：2023年8月18日）。评估偏倚风险和证据的确定性（PROSPERO：CRD42020178773）。
结果：我们确定了10项研究。两项研究报告说，在2年和7年期间，用MenC疫苗进行初次免疫的VE介于90％（74.9-96.1）和84.1％（41.5-95.7）之间。分别。8项研究报道了用MenC和/或MenACWY疫苗初次免疫的免疫原性,其中两个报告了-另外-加强免疫。初次免疫后，具有保护性rSBA滴度的参与者百分比很高，但在接下来的6年里有所减弱。7岁或以上的单个助推器似乎可以延长保护数年。
结论：12-23月龄的单剂量MenC或MenACWY疫苗可提供针对MenCIMD的强大保护。关于加强免疫的数据很少，但表明至少三年的长期保护。
方法：我们对年龄为12-23个月的初次和6-18岁的加强免疫参与者的VE和免疫原性（rSBA/hSBA滴度）的研究进行了系统评价（最后一次搜索：2023年8月18日）。评估偏倚风险和证据的确定性（PROSPERO：CRD42020178773）。
结果：我们确定了10项研究。两项研究报告说，在2年和7年期间，用MenC疫苗进行初次免疫的VE介于90％（74.9-96.1）和84.1％（41.5-95.7）之间。分别。8项研究报道了用MenC和/或MenACWY疫苗初次免疫的免疫原性,其中两个报告了-另外-加强免疫。初次免疫后，具有保护性rSBA滴度的参与者百分比很高，但在接下来的6年里有所减弱。7岁或以上的单个助推器似乎可以延长保护数年。
结论：12-23月龄的单剂量MenC或MenACWY疫苗可提供针对MenCIMD的强大保护。关于加强免疫的数据很少，但表明至少三年的长期保护。
